Symbols / GENE
GENE Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits Mon, 23 Feb 2026 18
- Best Gene-Editing Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool hu, 05 Feb 2026 08
- FDA fast-tracks gene therapy for rare storage disease, decision Aug. 23 - Stock Titan Mon, 23 Feb 2026 13
- Regenxbio stock drops on FDA setback for RGX-121 gene therapy (RGNX:NASDAQ) - Seeking Alpha ue, 10 Feb 2026 08
- Gene Munster Says Apple Stock's Tepid Reaction To Strong Earnings Beat Comes Down To One Thing: Investors Want More AI Substance - Yahoo Finance Sat, 31 Jan 2026 08
- Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - Clinical Trials Arena Fri, 07 Nov 2025 08
- Why This Beleaguered Gene-Editing Stock Just Surged - Investor's Business Daily ue, 27 Jan 2026 08
- Tesla's stock is moving in the right direction, says Deepwater Asset Management's Munster - CNBC Wed, 22 Oct 2025 07
- StockWatch: After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results - GEN - Genetic Engineering and Biotechnology News Sun, 19 Oct 2025 07
- Investing in the DNA of Tomorrow: Explore Gene Stocks and Genomics ETFs - Investing News Network hu, 28 Aug 2025 07
- Best Genomics Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool hu, 05 Feb 2026 08
- Assessing CRISPR Therapeutics Stock After 24.6% Drop and Breakthrough Gene Editing News - Yahoo Finance Sat, 08 Nov 2025 08
- Sarepta shares plunge 40% as future of its gene therapy appears at risk - CNBC Fri, 18 Jul 2025 07
- Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy? - Investor's Business Daily Mon, 26 Jan 2026 08
- Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock - Seeking Alpha Mon, 29 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for GENE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|